MedTrace Logo

CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors

NCT02094560 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2018-09-05

No results posted yet for this study

Summary

To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma (NSCLC), SCLC or biliary cancer who have progressed despite one or more previous chemotherapy line.

Conditions

  • Advanced Endstage Solid Carcinomas in Adults

Interventions

DRUG

CAP7.1

CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase

Sponsors & Collaborators

  • Mundipharma-EDO GmbH

    collaborator INDUSTRY

  • CellAct Pharma GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-08
Primary Completion
2015-09-08
Completion
2017-04-10

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094560 on ClinicalTrials.gov